The changing landscape for cervical screening

Medical Journal of Australia

Volumn 189, Issue 1, 2008, Pages 6-7

  Farnsworth, Annabelle ^a  

^a DOUGLASS HANLY MOIR PATHOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

AUSTRALIA; CANCER GRADING; CANCER INVASION; CANCER RISK; CANCER SCREENING; COLPOSCOPY; COMPUTER ASSISTED DIAGNOSIS; CONDYLOMA ACUMINATUM; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; DISEASE REGISTRY; DRUG COST; EDITORIAL; GYNECOLOGICAL EXAMINATION; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; MICROBIOLOGICAL EXAMINATION; POPULATION RESEARCH; PREVENTIVE HEALTH SERVICE; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SEROLOGY; SEXUAL BEHAVIOR; UTERINE CERVIX CANCER; VACCINATION; VIRUS STRAIN; WART VIRUS;

EID: 49649086064     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2008.tb01884.x     Document Type: Editorial

References (10)

1. Australian Institute of Health and Welfare. Cervical screening in Australia 2004-2005. Canberra: AIHW, 2007: ix. (AIHW Cat. No. CAN 33.)
2. Walboomers JM, Jacobs MW, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
3. Dziura B, Quinn S, Richard K. Performance of an imaging system vs manual screening in the detection of squamous intraepithelial lesions of the uterine cervix. Acta Cytol 2006; 50: 309-311.
4. Davey E, d'Assuncao J, Irwig L, et al. Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: a prospective study. BMJ 2007; 335: 31-35.
5. Pharmaceutical Benefits Advisory Committee. Public summary document: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) recombinant vaccine injection, 0.5ml Gardasil®. Canberra: PBAC, 2006. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ F671233BC33FB47FCA25728E001C5974/$File/gardasil.pdf (accessed Jun 2008).
6. Davies P, Arbyn M, Dillner J, et al. A report on the current status of European Research on the use of human papillomavirus testing for primary cervical cancer screening. Int J Cancer 2006; 118: 791-796.
7. Burchell AN, Winer RL, de Sanjosé S, Franco EL. Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006; 24 Suppl 3: S52-S61.
8. Royal Australian and New Zealand College of Obstetricians and Gynaecologists. College statement: guidelines for HPV vaccine. Melbourne: RANZCOG, 2007. http://www.ranzcog.edu.au/publications/ statements/C-gyn18-Guidelines-for-HPV-Vaccine.pdf (accessed Mar 2008).
9. Castle PE, Sideri M, Jeronimo J, et al. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 2007; 197: 356.e1-356.e6.
10. Davey E, Barratt A, Irwig L, et al. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 2006; 367: 122-132.